FILE - This Oct. 14, 2015, file photo, shows the U.S. Food & Drug Administration campus in Silver Spring, Md. On Wednesday, Oct. 25, 2017, the FDA rejected an experimental drug for a common type of muscular dystrophy. The drug from PTC Therapeutics was intended for Duchenne muscular dystrophy patients with a certain genetic mutation. The muscle-destroying disorder affects 1 in 3,500 to 5,000 boys in the U.S. (AP Photo/Andrew Harnik, File)
Featured Photo Galleries
Trump Transition: Here are the people Trump has picked for key positions so far
President-elect Donald Trump has announced a flurry of picks for his incoming administration. Get full coverage of the Trump transition from The Washingon Times.
Trump dances onstage, takes post-election nation by storm
President-elect Trump dances onstage
